PharmaSaga to Compete for the Startup Pitch Competition Championship at BIO North America.

The US BIO International Convention is a major global event on the global biotechnology and pharmaceutical sector calendar, bringing together top pharmaceutical companies, biotech startups, and investors from around the world. The convention offers extensive opportunities for business collaboration, particularly in licensing, technology transfer, and clinical partnerships.

The main goal of our participation in this exhibition is to engage with the top ten international pharmaceutical companies in the diabetes field.

Our core product, the diabetes drug PS1, is an innovative therapy with first-in-class potential. It works by inhibiting PDIA4, reducing ROS (reactive oxygen species), and preserving pancreatic islet cell viability and functionality. We extensively discussed its potential with the top ten and other international pharmaceutical companies both before and after the conference. This exhibition is a crucial opportunity for both parties to hold further face-to-face negotiations.

Furthermore, we are deeply honored to have been selected again for the Start-up Stadium, a competition designed to discover global biotech startups with groundbreaking technologies. Among the 57 selected teams worldwide, we are one of only two teams from Asia. 

We competed for the world championship on June 17th. Championship participation not only serves as recognition of our technology but also provides us with increased exposure and opportunities for collaboration.